HTBX Heat Biologics Inc.

0.57
+0.01  (+2%)
Previous Close 0.56
Open 0.56
Price To Book 0.73
Market Cap 19,410,609
Shares 34,065,652
Volume 43,122
Short Ratio
Av. Daily Volume 246,222

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 data due 4Q 2019.
HS-110 and nivolumab (Opdivo)
Non-small cell lung cancer (NSCLC)
Phase 2 trial did not meet primary endpoint - November 30, 2016.
HS-410
Bladder cancer
Phase 1b data released December 6, 2016.
HS-110
Non-small cell lung cancer (NSCLC)

Latest News

  1. Heat Biologics Reports Second Quarter 2019 Results and Provides Corporate Update
  2. Heat Biologics Announces FDA Clearance of IND Application to Begin Phase 1 Trial of HS-130 in Combination with Heat’s HS-110
  3. Heat Biologics CEO and Lead Director to Participate in German Investor Forums
  4. What You Must Know About Heat Biologics, Inc.'s (NASDAQ:HTBX) Beta Value
  5. Heat Biologics Completes Enrollment in Phase 2 Non-Small Cell Lung Cancer Trial
  6. HTBX: INDs To Be Filed Soon
  7. Heat Biologics Announces Promising Interim Phase 2 Lung Cancer Data Suggesting that HS-110 Plus Nivolumab May Restore Clinical Benefit After Checkpoint Inhibitor Treatment Failure
  8. Is Heat Biologics, Inc.'s (NASDAQ:HTBX) CEO Overpaid Relative To Its Peers?
  9. Heat Biologics to Present at the 20th Annual B. Riley FBR Institutional Investor Conference
  10. Heat Biologics Reports First Quarter 2019 Results and Provides Corporate Update
  11. Heat Biologics Lead Director to Present at the ChinaBio 2019 Conference in Shanghai
  12. Heat Biologics CEO to Present at the ThinkEquity Conference in New York City
  13. HTBX: 2018 Financial & Operational Results
  14. Heat Biologics Delivers Poster Presentation at the AACR Annual Meeting 2019
  15. Heat Biologics Reports 2018 Results and Provides Corporate Update
  16. Heat Biologics to Present at the Chinese Society for Clinical Oncology Conference on Immunotherapy
  17. HTBX: HS-110 Interim Update
  18. Heat Biologics Lead Director to Chair Oncology Roundtable Discussion at WuXi Healthcare Forum in Shanghai
  19. Heat Biologics Presents Interim Phase 2 Lung Cancer Data on HS-110 + Nivolumab at ASCO-SITC Clinical Immuno-Oncology Symposium
  20. These Four Healthcare Stocks Are Heating Up On Tuesday